Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
Henríquez López I, González-San Segundo C, Vegas JO, Gutierrez C, Hervas A, Cabeza Rodriguez MÁ, Valero Albarrán J, Rodríguez Villalba S, Álvarez Gonzalez A, Sancho Pardo G, Zapatero A, Álvaro PC. Henríquez López I, et al. Radiother Oncol. 2019 Dec;141:156-163. doi: 10.1016/j.radonc.2019.09.006. Epub 2019 Sep 27. Radiother Oncol. 2019. PMID: 31570236
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodríguez MA, Macias V, Pedro Olive A, Casas F, Boladeras A, de Vidales CM, Vazquez de la Torre ML, Villà S, Perez de la Haza A, Calvo FA. Zapatero A, et al. Lancet Oncol. 2015 Mar;16(3):320-7. doi: 10.1016/S1470-2045(15)70045-8. Epub 2015 Feb 19. Lancet Oncol. 2015. PMID: 25702876 Clinical Trial.
Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.
López Torrecilla J, Hervás A, Zapatero A, Gómez Caamaño A, Macías V, Herruzo I, Maldonado X, Gómez Iturriaga A, Casas F, González San Segundo C. López Torrecilla J, et al. Rep Pract Oncol Radiother. 2015 Jul-Aug;20(4):259-72. doi: 10.1016/j.rpor.2015.04.003. Epub 2015 May 30. Rep Pract Oncol Radiother. 2015. PMID: 26109913 Free PMC article. Review.
Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.
López-Torrecilla J, Boladeras A, Cabeza MA, Zapatero A, Jove J, Esteban LM, Henriquez I, Casaña M, González-San Segundo C, Gómez-Caamaño A, Mengual JL, Hervás A, Muñoz JL, Sanz G. López-Torrecilla J, et al. Strahlenther Onkol. 2015 Oct;191(10):792-800. doi: 10.1007/s00066-015-0866-7. Epub 2015 Jul 9. Strahlenther Onkol. 2015. PMID: 26156249
Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272].
López Torrecilla J, Hervás A, Zapatero A, Gómez Caamaño A, Macías V, Herruzo I, Maldonado X, Gómez Iturriaga A, Casas F, González San Segundo C. López Torrecilla J, et al. Rep Pract Oncol Radiother. 2016 Jan-Feb;21(1):90-2. doi: 10.1016/j.rpor.2015.06.006. Epub 2015 Jul 20. Rep Pract Oncol Radiother. 2016. PMID: 26900365 Free PMC article.
Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial.
Zapatero A, Guerrero A, Maldonado X, Álvarez A, González-San Segundo C, Cabeza Rodriguez MA, Macías V, Pedro Olive A, Casas F, Boladeras A, Martín de Vidales C, Vázquez de la Torre ML, Calvo FA. Zapatero A, et al. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):341-348. doi: 10.1016/j.ijrobp.2016.06.2445. Epub 2016 Jun 22. Int J Radiat Oncol Biol Phys. 2016. PMID: 27598804 Clinical Trial.
Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study.
Casas F, Henríquez I, Bejar A, Maldonado X, Alvarez A, González-Sansegundo C, Boladeras A, Ferrer F, Hervás A, Herruzo I, Caro M, Rodriguez I, Ferrer C. Casas F, et al. Clin Transl Oncol. 2017 Mar;19(3):373-378. doi: 10.1007/s12094-016-1538-5. Epub 2016 Oct 21. Clin Transl Oncol. 2017. PMID: 27770397 Clinical Trial.
Predictors of urinary and rectal toxicity after external conformed radiation therapy in prostate cancer: Correlation between clinical, tumour and dosimetric parameters and radical and postoperative radiation therapy.
Martínez-Arribas CM, González-San Segundo C, Cuesta-Álvaro P, Calvo-Manuel FA. Martínez-Arribas CM, et al. Actas Urol Esp. 2017 Dec;41(10):615-623. doi: 10.1016/j.acuro.2017.03.010. Epub 2017 Jun 16. Actas Urol Esp. 2017. PMID: 28625534 English, Spanish.
49 results